MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
BusinessWeek
November 21, 2005
Gene G. Marcial
Salix Pharmaceuticals: What The Gut Tells You The small fry in gastrointestinal drugs is a pure play in that growing market. mark for My Articles similar articles
The Motley Fool
February 24, 2011
Brian D. Pacampara
Salix Pharmaceuticals Shares Plunged: What You Need to Know Shares of Salix Pharmaceuticals plummeted more than 20% after the company said it expects the Food and Drug Administration to deny its bid to gain expanded approval for its gastrointestinal antibiotic Xifaxan. mark for My Articles similar articles
The Motley Fool
May 10, 2011
Frank Vinluan
Salix Sued by Partner for "Breach" Over HIV-Associated Drug Who will take this blockbuster drug to market? mark for My Articles similar articles
The Motley Fool
February 25, 2011
Brian Orelli
When the Companies Know, Investors Should, Too Why don't more companies preannounce FDA rejections? mark for My Articles similar articles
The Motley Fool
February 26, 2011
Brian Orelli
FDA Applications and a Look Ahead It isn't pretty. mark for My Articles similar articles
The Motley Fool
December 21, 2004
Charly Travers
Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc. mark for My Articles similar articles
The Motley Fool
November 30, 2010
Brian Orelli
Soros Is Buying Health Care. Should You? Some but not all of his picks look good to me. mark for My Articles similar articles
Chemistry World
March 25, 2015
Phillip Broadwith
Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals. mark for My Articles similar articles
The Motley Fool
December 20, 2011
Brian D. Pacampara
Salix Pharmaceuticals Shares Popped: What You Need to Know Shares of drugmaker Salix Pharmaceuticals climbed as high as 10.5% on Tuesday after the company reported positive phase-3 data for an oral version of its constipation treatment, Relistor. mark for My Articles similar articles
Chemistry World
February 23, 2015
Phillip Broadwith
Valeant to buy Salix for $14.5bn Serial acquirer Valeant has agreed to buy gastroenterology specialist Salix Pharmaceuticals for $14.5 billion mark for My Articles similar articles